Non-invasive markers for staging fibrosis in patients with chronic hepatitis Delta
- VernacularTitle:Дельта вирүст хепатиттай өвчтөнүүдэд хатгалтын бус аргаар элэгний фиброзийн зэргийг тодорхойлсон дүн
- Author:
Sarantuya G
1
,
2
;
Sumiya D
1
;
Selenge J
3
;
Uranbailgal E
2
;
Otgonbayar R
2
;
Munkhbat B
2
;
Bira N
2
Author Information
1. Intermed Hospital
2. Mongolian National University of Medical Sciences
3. Мungunguur Hospital
- Publication Type:Journal Article
- Keywords:
Fibroscan;
hepatitis Delta;
liver fibrosis;
M2BPGi;
non-invasive markers
- From:Mongolian Medical Sciences
2021;195(1):18-24
- CountryMongolia
- Language:Mongolian
-
Abstract:
Introduction:Determining stages of liver fibrosis in chronic liver disease is essential for clinical practice such as
decision making on medical treatment, setting the interval of follow-up examination for its complication,
screening intervals for hepatocellular carcinoma.
Goal:We compared non-invasive fibrosis markers among the patients with chronic hepatitis Delta.
Materials and Methods:Totally 70 patients with chronic hepatitis D enrolled into this study. The blood samples were examined
for complete blood count, liver function test and serum M2BPGi level. Non-invasive markers such
as AAR, APRI, Fib-4 scores were calculated. Those with AAR >1, APRI >0.7, FIB-4 >1.45 were
considered with advanced fibrosis. All patients underwent liver stiffness measurement using FibroScan
M2 probe. The cutoff values of FibroScan for advanced fibrosis were 9 kPa for patient with normal
transaminase level and 11 kPa for patients with elevated transaminase.
Results:Advanced fibrosis was observed in 25.7%, 38.6% and 38.6% by AAR, APRI and Fib-4 score,
respectively. When cut-off levels of serum M2BPGi for advanced fibrosis was 2.2 COI, 35.7% had
advanced fibrosis. FibroScan tests showed 34.4% had advanced fibrosis. The AUROC of M2BPGi
were 0.894 and 0.827 for predicting advanced fibrosis and liver cirrhosis.
Conclusion:Serum M2BPGi and FibroScan would be reliable diagnostic tool for identifying liver
fibrosis in Mongolian patients with chronic hepatitis D.
- Full text:2021-195(1)-18-24.pdf
